Other vaccine trials, including dendritic cell vaccines where DCs are generated to present antigens targeting GBM cells (e.g., HER2, IL13Ra2), have shown mixed results and are discussed in a comprehensive review by Sener et al. [186]. This evidence concerns the gene ERBB2 and glioblastoma.